PORTFOLIO

Prosciens internal portfolio currently consists of three main projects:

Cancer metabolism. We are currently exploring the therapeutic potential of profiting from the differential metabolic profile observed in most cancer cells (Warburg effect) in order to restore normal apoptotic cell fate.  We have succeeded to build an international multidisciplinary research network (see PARTNERS section). The preliminary results are encouraging.

Neurodegenerative diseases. We are starting to explore the therapeutic potential of microtubule stabilisation for the treatment of different neurodegenerative syndromes such as Parkinson’s and Alzheimer’s.

Covalent COX inhibitors. Over a century after its first therapeutic application, aspirin remains the only approved COX inhibitor that exert its effect by covalently modifying the enzyme. We are currently developing a novel family of covalent COX inhibitors.